Dataset Information


Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria.

ABSTRACT: The clinical management of paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening hematologic disease, has fundamentally improved with the introduction of a therapeutic that prevents complement-mediated intravascular hemolysis. However, a considerable fraction of PNH patients show insufficient treatment response and remain transfusion dependent. Because the current treatment only prevents C5-induced lysis but not upstream C3 activation, it has been speculated that ongoing opsonization with C3 fragments leads to recognition and phagocytosis of PNH erythrocytes by immune cells. Here, for the first time, we provide experimental evidence for such extravascular hemolysis and demonstrate that PNH erythrocytes from anti-C5-treated patients are phagocytosed by activated monocytes in vitro. Importantly, we show that this uptake can be mediated by the end-stage opsonin C3dg, which is not traditionally considered a phagocytic marker, via interaction with complement receptor 3 (CR3). Interaction studies confirmed that C3dg itself can act as a ligand for the binding domain of CR3. The degree of C3dg-mediated erythrophagocytosis in samples from different PNH patients correlated well with the individual level of C3dg opsonization. This finding may guide future treatment options for PNH but also has potential implications for the description and management of other complement-mediated diseases.


PROVIDER: S-EPMC4536542 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC3968392 | BioStudies
1000-01-01 | S-EPMC4383744 | BioStudies
2018-01-01 | S-EPMC6060635 | BioStudies
2020-01-01 | S-EPMC7387411 | BioStudies
2019-01-01 | S-EPMC6587878 | BioStudies
2016-01-01 | S-EPMC4747809 | BioStudies
1000-01-01 | S-EPMC4000462 | BioStudies
2017-01-01 | S-EPMC5815388 | BioStudies
2014-01-01 | S-EPMC4250431 | BioStudies
2019-01-01 | S-EPMC6657537 | BioStudies